Cardiff Oncology CRDF 深 沪
等待开盘 06-03 09:30:00 美东时间
1.5299
+0.050
+3.37%
华盛通- 最 高2.00
- 今 开1.48
- 成交量 268.08万股
- 最 低 1.40
- 昨 收 1.48
- 总市值 6.63万
- 52周最高 4.555
- 市盈率 静 --
- 换手率 6190.41%
- 52周最低 1.40
- 委 比 -75.61%
- 总股本 4.33万
- 历史最高 977.76
- 量 比 1.29
- 振 幅 40.54%
- 历史最低 0.701
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TD Cowen Downgrades Cardiff Oncology to Hold
TD Cowen analyst Marc Frahm downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold.
06-01 22:40
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
06-01 20:57
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed Cardiff's legal stance.
05-21 02:11
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus
Cardiff Oncology shares fell 32% after a sudden CEO and CFO exit, trial strategy changes, and a negative analyst update that cut success odds and market potential.
01-28 19:23
Cardiff Oncology Names Mani Mohindru Interim CEO
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support
01-28 00:17
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology appoints Roger Sidhu, MD, as Chief Medical Officer, with over 20 years of oncology leadership experience. The company will share additional clinical data from its Phase 2 CRDF-004 trial in RAS-mutated metastatic colorectal cancer during a conference call on July 29, 2025.
2025-06-17 20:05
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
<p>Cardiff Oncology reported positive results from a Phase 1b trial of onvansertib combined with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients. The trial showed a 40% objective response rate at the highest dose of onvansertib, with the combination being well-tolerated and exhibiting manageable toxicity. The findings support further exploration of this therapeutic combination for mTNBC.</p>
2025-06-02 20:05
Craig-Hallum Initiates Coverage On Cardiff Oncology with Buy Rating, Announces Price Target of $8
Craig-Hallum analyst Albert Lowe initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Buy rating and announces Price Target of $8.
2024-09-06 20:26
